2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.119 Firas Badin NACLC23 Abstract

PP01.119 Firas Badin NACLC23 Abstract

Pdf Summary

The study provides an update on the clinical efficacy and safety of first-line nivolumab (N) and ipilimumab (I), in combination with chemotherapy (C), in patients with metastatic non-small cell lung cancer (mNSCLC). The patients were randomized to receive either N and I with 2 cycles of C or 4 cycles of C alone. The results show that N and I continued to provide a durable overall survival (OS) benefit compared to C alone, with a hazard ratio (HR) of 0.74. This benefit was seen across different subgroups based on tumor PD-L1 expression and histology. Among patients who discontinued N and I due to treatment-related adverse events, the 4-year OS rate was 41%. The median number of doses of immunotherapy received was 7 for N and 3 for I. No new safety signals were identified. <br /><br />The data from this study support the use of N and I as an efficacious first-line treatment option for patients with mNSCLC, especially those with high unmet needs such as tumor PD-L1 expression of 1% or higher and squamous histology. The study highlights the long-term, durable efficacy of N and I, regardless of tumor PD-L1 expression or histology. Discontinuation of N and I due to treatment-related adverse events did not negatively impact long-term outcomes. <br /><br />In summary, the combination of N and I with chemotherapy provides a durable survival benefit for patients with mNSCLC, regardless of tumor PD-L1 expression or histology. This combination should be considered as a first-line treatment option, particularly for patients with high unmet needs. The study also demonstrates the importance of managing treatment-related adverse events to ensure optimal long-term outcomes.

Keywords

clinical efficacy

safety

nivolumab

ipilimumab

chemotherapy

metastatic non-small cell lung cancer

overall survival benefit

tumor PD-L1 expression

histology

treatment-related adverse events